A Novel Blood Test as a Biomarker in Mental Health
Recruiting now NCT06856161
Run by Fraser Health · for 19 and older · All sexes
What this study is about
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis/Schizophrenia (PSY).
Who can join (things the study team will check)
✅ You may be able to join if…
- Suspected, new onset or established depression.
- First episode of psychosis or suspected/established schizophrenia. IV. In the opinion of the Investigator, the participant will likely be able to complete the standardized mental health questionnaires administered in each study visit.
Where this trial is running
- Royal Columbian Hospital, New Westminster, British Columbia, Canada
Who to contact
Jessica Wittmann · +1 (236) 332-6575 · LeadingMH@fraserhealth.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06856161.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.